Tag: #irishtechnews

Skullcandy launch the Push Ultra, Indy Evo,Indy Fuel and Sesh Evo True Wireless. #Skullcandy #TrueWireless

Skullcandy Inc., the original lifestyle audio brand, continues to dominate the true wireless earbud category with the launch of four feature-rich True Wireless earbuds –  Push Ultra, Indy Evo, Indy Fuel and Sesh Evo. Each of the new releases are jam-packed with enhanced features including high-quality audio, extended battery life and Tile™ finding technology, guaranteeing your music is never left behind.

 

“The launch of our newest True Wireless earbuds were designed to take this rapidly growing category to the next level,” said Jason Hodell, CEO of Skullcandy. “This expansion takes our best selling products and enhances them based on the feedback we’ve received from customers including improvements in battery life, connectivity, comfort and fit.   We have also added new technology features like wireless charging, solo bud use and Tile™ technology to truly offer an experience unlike any other on the market.”

 

Push Ultra is Skullcandy’s brand new listening experience within its growing Adventure Audio category – the ultimate companion for any adventure or workout. The earbud features a moldable ear hook for an ultra-secure customized fit, with a convenient Stay-Aware earbud design. Housed in a thoughtfully designed protective wireless charging case, Push Ultra is loaded with up to 40 hours of listening time (6 hours in each earbud and an additional 34 hours in the charging case).  The buds are IP67 sweatproof, waterproof and dustproof, Tile™ enabled and have full controls on each bud that allow for solo bud use.

 

“Tile’s technology helps people manage life’s everyday disruptions,” said CJ Prober, CEO of Tile. “Disappearing headphones can be inconvenient and expensive, but by expanding our partnership with Skullcandy to make their latest true wireless lineup findable, users can feel free and confident that their favourite pair of earbuds will be ready when they need them. Once activated, Tile helps users ring their earbuds, see their location on a map or employ Tile’s global network to find them.”

 

Indy gets upgraded to Indy Evo and Indy Fuel, the newest evolution of the family. Now with extended battery life, improved connectivity, enhanced fit, and Skullcandy app compatibility, this generation is even more feature-rich. Audio quality enhancements, including titanium-coated drivers and expertly crafted EQ and ambient-listening modes, deliver a premium listening experience.

 

In addition to expanding the most popular True Wireless earbud franchise, Skullcandy is also expanding its entry-level True Wireless offering with Sesh Evo. Sesh Evo makes it easier than ever to jump into True Wireless with easy setup, simple controls, and IP55-rated durability.

 

Additional details on the new features found in Skullcandy’s latest slate of True Wireless earbuds include:

 

  • PUSH ULTRA – For a zero boundary, max performance listening experience, look no further than Push Ultra. The sweat, water, and dustproof earbud that can stand up to the sweatiest endeavours and be submerged in 1 meter of water for 30 minutes.  With rapid-charging capability of 2 hours of charge in 10 minutes, Push Ultra is available for £119.99 in True Black, Electric Yellow and Bleached Blue.

 

  • INDY EVO – True freedom gets amplified with Indy Evo, the earbud that lets you take music everywhere, going totally wireless without overpriced earbuds that you’re afraid to use, lose, or both. With up to 30 hours of battery life, Indy Evo comes in Pure Mint, Chill Gray, Deep Red, and True Black and is available for £89.99.

 

  • INDY FUEL – Indy Fuel takes truly wireless to another level. On top of all the features of Indy Evo like the enhanced fit, size and call, track, and volume control, Indy Fuel also comes with a wireless charging case. Get true freedom with effortless charging, Indy Fuel is available for £109.99 in True Black.

 

  • SESH EVO – Go truly wireless and get longer listening with Sesh Evo. With improved connectivity and acoustics, and a full suite of media controls, Sesh Evo packs all the essentials into a small form factor. These earbuds have up to 24 hours of battery life, come in Bleached Blue, Pure Mint, Deep Red and True Black and are available for £59.99.

MyCHI App for Staff – How Children’s Health Ireland are Supporting Staff through Coronavirus #CHI #Thrive

Children’s Health Ireland (CHI) is responsible for the delivery of acute paediatric services for children, provided in the three Dublin children’s hospital locations at Crumlin, Temple Street and Tallaght and a paediatric outpatient and urgent care centre based on the campus at Connolly Hospital, Blanchardstown.

With over 4,000 people working in CHI across five locations, most are not desk-based; communication and sharing information has therefore been a challenge. The development of the new organisation, bringing three hospitals together into one on 1 January 2019 and the opening of CHI at Connolly in July 2019 also increased the need to communicate better and to engage teams through these organisational and cultural changes.

To meet the challenges, Trevor Murphy, Director of Human Resources started to look at ways in which staff and management in individual hospitals and the change programme could more effectively communicate and share information with each other.

The need for effective communication and information sharing reached a critical point with the spread of COVID-19 bringing new challenges to CHI to communicate in a timely and pervasive means with their staff. Trevor evaluated several options before deciding to proceed with Thrive. Within three weeks, CHI were up and running, using Thrive’s communication platform and app, which has be branded ‘MyCHI’, with ongoing assistance from the Thrive team.

Commenting on the new app for staff MyCHI, Trevor Murphy, Director of Human Resources said; “A massive and sincere thanks to all the Thrive team for ‘the can do’ attitude in assisting us in launching our employee app MyCHI. It is hugely welcomed by all as a great support for communicating key and important updates, information and supports for our staff at this very difficult time.

The initial feedback from staff has been overwhelmingly positive and we are excited to roll it out to our staff across all our sites, in particularly those who are working remotely due to the current guidelines on physical and social distancing

With our programme for change in preparation for our move to the new children’s hospital and the current health crisis we are facing, there has never been a more important time for us to ensure our colleagues are connected, sharing and receiving important information and feel fully supported and recognised.

Team Thrive are delighted to help and welcome CHI as a new client and we look forward to working with their team to ensure their employee communications app is engaging and reaching all team members in these challenging times.”

James Scott CEO, Co-Founder of Thrive said; “During this time of uncertainty, effective communication is vital. We are so happy that the Thrive platform and app are genuinely helping people and organisations during this challenging time. We have made adjustments to our contracts and pricing in order to be as flexible as possible to help as many organisations as we can and are delighted to have CHI join our client base.”

Diaceutics unveils name and initial plan for €26M global precision medicine diagnostic network. #DXRX #Diaceutics

Diaceutics PLC, today announces DXRX, the world’s first Diagnostic Network for precision medicine which will enable the company to scale its business to meet fast growing demand in the precision medicine market. It represents the culmination of a €26m million investment by Diaceutics in software and data.

DXRX addresses stakeholder collaboration problems which have led to a suboptimal testing ecosystem and has resulted in most precision medicines reaching only 50% of eligible patients in oncology.

The new platform enables Diaceutics to meet the need for a global standardised diagnostic process by offering an end-to-end solution for the development and commercialisation of precision medicine diagnostic testing. It will significantly enhance Diaceutics’ service offering and enable it to meet the increased market demand being created by 1,000 new precision medicines currently in pharmaceutical company pipelines.

Diaceutics has spent the last 10 years building relationships with more than 2500 laboratories worldwide. DXRX enables these laboratories to be integrated into a network providing a global flow of testing data, thus placing those labs at the centre of precision medicine.

The need for stakeholder collaboration has been addressed by building alliances with industry leading service providers in areas such as pathology training, health economics, reference standards, EQA and digital enablement. DXRX will make these alliances and its real-world data repository available to its network of pharmaceutical, laboratory and diagnostic partners.

Ryan Keeling, Chief Innovation Officer, Diaceutics

Diaceutics’ Chief Innovation Officer, Ryan Keeling, commented, “Given the richness of the data we have, Diaceutics has been uniquely positioned to identify that, as an industry, we have been getting it wrong when it comes to patient testing for precision medicines.

“Our evidence, our partners and our experience tell us that there is a better way and that the time for that better way is now. We believe that DXRX is the model that can deliver significantly more value for all stakeholders, and most importantly, a model which enables every patient to get the treatment they deserve.

“The era of a therapy being launched with a single companion diagnostic option is behind us. We need to consider the global needs of our patients and the regional restrictions commonly faced. This calls for pharma to think beyond a one-size-fits-all approach to testing and embrace the democratisation of testing.

“Our experience of working on every precision medicine currently on market puts Diaceutics in a unique position to advance a significantly better industry model and deliver significant new value for all stakeholders in precision medicine.”

Onboarding of laboratory and diagnostic partners to DXRX will commence in Q3 2020, with pharmaceutical clients gaining access in Q4.

DXRX is industry shorthand for diagnostics and therapy. For more information visit dxrx.diaceutics.com.